Literature DB >> 9066635

Loss of heterozygosity at chromosome 7q in human breast cancer: association with clinical variables.

A K Kristjansson1, G Eiriksdottir, G Ragnarsson, A Sigurdsson, J Gudmundsson, R B Barkardottir, J G Jonasson, V Egilsson, S Ingvarsson.   

Abstract

In this study 238 human primary breast cancers were analysed with 9 polymorphic microsatellite markers specific to region 7q21-q35 on chromosome 7. LOH was observed at one or more marker in 82 cases or (34%). The deletions were evenly distributed throughout the region. Patients were divided into two groups according to whether LOH was observed in their tumours or not, and tested for association with overall survival, the clinicopathological features: steroid receptor content, tumour size, node status, DNA ploidy and S-phase fraction, and LOH at other chromosomal regions. An association was found between 7q LOH and high S-phase fraction. An association was found between LOH at 7q and LOH at 1p, 3p, 9p, 13q and 17q. These results suggest the location of a putative tumour suppressor gene at chromosome 7q21-q35 that, in combination with other deletions, might enhance tumour growth.

Entities:  

Mesh:

Year:  1997        PMID: 9066635

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

2.  Haploinsufficient tumor suppressor genes.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Adv Med Biol       Date:  2017 1st Quarter

3.  Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals.

Authors:  N J Marston; W J Richards; D Hughes; D Bertwistle; C J Marshall; A Ashworth
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

4.  Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

5.  Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci.

Authors:  H Liang; J Fairman; D F Claxton; P C Nowell; E D Green; L Nagarajan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling.

Authors:  Angela J Glading; Mark H Ginsberg
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

7.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

8.  Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.

Authors:  Xiaohui Bi; Meera Hameed; Neena Mirani; Erica Maria Pimenta; Jason Anari; Betsy J Barnes
Journal:  Breast Cancer Res       Date:  2011-11-04       Impact factor: 6.466

9.  Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.

Authors:  C Huiping; J R Sigurgeirsdottir; J G Jonasson; G Eiriksdottir; J T Johannsdottir; V Egilsson; S Ingvarsson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

10.  Dmp1α inhibits HER2/neu-induced mammary tumorigenesis.

Authors:  Elizabeth A Fry; Pankaj Taneja; Dejan Maglic; Sinan Zhu; Guangchao Sui; Kazushi Inoue
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.